Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments (2016 - 2026)

Rocket Pharmaceuticals has reported Change in Acquisitions & Divestments for 10 years, with the latest figure at $66.2 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 19.46% year-over-year to $66.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $364.8 million (changed 0.01% YoY) and the FY2025 annual result came in at $380.8 million, down 0.7% from the prior year.
• Change in Acquisitions & Divestments slipped to $66.2 million in Q1 2026 per RCKT's latest filing, from $91.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $123.0 million in Q3 2025 and troughed at $50.8 million in Q4 2022.
• A 5-year average of $83.1 million and a median of $82.3 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments dropped 23.97% in 2023, then soared 62.05% in 2024.
• Over 5 years, Change in Acquisitions & Divestments stood at $50.8 million in 2022, then soared by 42.35% to $72.3 million in 2023, then rose by 19.54% to $86.5 million in 2024, then increased by 5.22% to $91.0 million in 2025, then declined by 27.2% to $66.2 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $66.2 million, $91.0 million, and $123.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.